
Opinion|Videos|August 5, 2024
Dr Hanna & Hope Rugo, MD Shares Potential Role of Improving Access to CDK4/6 Inhibitors
Drs. Hanna and Rugo discuss possible access improvements in regards to CDK4/6 inhibitors.
Advertisement
Video content above is prompted by the following question(s):
- What is the potential role of value-based pricing models or alternative payment arrangements in improving access to CDK4/6 inhibitors for eligible patients?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves First-in-Class Optune Pax Device for Pancreatic Cancer
2
Contributor: American Patients vs Foreign Governments—A Tale of 2 Value Sets
3
Bipartisan Break Up Big Medicine Act Targets Vertical Integration in Health Care
4
3-Year EPCORE NHL-1 Data Published Showing 53% Have Deep, Durable Remission
5
















